CO6382122A2 - Compuestos útiles para inhibir chk1 - Google Patents

Compuestos útiles para inhibir chk1

Info

Publication number
CO6382122A2
CO6382122A2 CO11074829A CO11074829A CO6382122A2 CO 6382122 A2 CO6382122 A2 CO 6382122A2 CO 11074829 A CO11074829 A CO 11074829A CO 11074829 A CO11074829 A CO 11074829A CO 6382122 A2 CO6382122 A2 CO 6382122A2
Authority
CO
Colombia
Prior art keywords
useful compounds
inhibit chk1
chk1
inhibit
useful
Prior art date
Application number
CO11074829A
Other languages
English (en)
Spanish (es)
Inventor
Francine Farouz
Holcomb Ryan Coastworth
Ramesh Kasar
Myers Steven Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6382122A2 publication Critical patent/CO6382122A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO11074829A 2008-12-17 2011-06-15 Compuestos útiles para inhibir chk1 CO6382122A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
CO6382122A2 true CO6382122A2 (es) 2012-02-15

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11074829A CO6382122A2 (es) 2008-12-17 2011-06-15 Compuestos útiles para inhibir chk1

Country Status (37)

Country Link
EP (1) EP2379532B1 (OSRAM)
JP (1) JP5705743B2 (OSRAM)
KR (1) KR101301777B1 (OSRAM)
CN (1) CN102245597B (OSRAM)
AR (1) AR074471A1 (OSRAM)
AU (1) AU2009333433B2 (OSRAM)
BR (1) BRPI0922468A2 (OSRAM)
CA (1) CA2746423C (OSRAM)
CL (1) CL2011001463A1 (OSRAM)
CO (1) CO6382122A2 (OSRAM)
CR (1) CR20110339A (OSRAM)
CY (1) CY1113930T1 (OSRAM)
DK (1) DK2379532T3 (OSRAM)
DO (1) DOP2011000185A (OSRAM)
EA (1) EA018118B1 (OSRAM)
EC (1) ECSP11011136A (OSRAM)
ES (1) ES2401558T3 (OSRAM)
HN (1) HN2011001446A (OSRAM)
HR (1) HRP20130167T1 (OSRAM)
IL (1) IL213160A (OSRAM)
JO (1) JO2886B1 (OSRAM)
MA (1) MA32901B1 (OSRAM)
MX (1) MX2011006603A (OSRAM)
MY (1) MY156998A (OSRAM)
NZ (1) NZ593440A (OSRAM)
PA (1) PA8850801A1 (OSRAM)
PE (1) PE20120077A1 (OSRAM)
PL (1) PL2379532T3 (OSRAM)
PT (1) PT2379532E (OSRAM)
RS (1) RS52739B (OSRAM)
SG (1) SG172222A1 (OSRAM)
SI (1) SI2379532T1 (OSRAM)
TN (1) TN2011000298A1 (OSRAM)
TW (1) TWI436996B (OSRAM)
UA (1) UA101998C2 (OSRAM)
WO (1) WO2010077758A1 (OSRAM)
ZA (1) ZA201103946B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
AR106772A1 (es) * 2015-12-07 2018-02-14 Lilly Co Eli Sales de (s)-lactato
US20180228795A1 (en) * 2015-12-15 2018-08-16 Eli Lilly And Company Combination therapy for cancer
CN108601781B (zh) * 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114746413B (zh) * 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
MX2023006364A (es) 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
JP2024520481A (ja) * 2021-05-27 2024-05-24 バウンドレス バイオ，インク． チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
EP4455134A4 (en) 2021-12-24 2025-10-08 Sumitomo Pharma Co Ltd 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON
CN119403571A (zh) * 2022-05-27 2025-02-07 住友制药株式会社 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
JO2886B1 (en) 2015-03-15
KR101301777B1 (ko) 2013-08-30
MA32901B1 (fr) 2011-12-01
DK2379532T3 (da) 2013-03-18
MY156998A (en) 2016-04-15
CL2011001463A1 (es) 2012-01-20
DOP2011000185A (es) 2017-12-15
CA2746423A1 (en) 2010-07-08
PL2379532T3 (pl) 2013-07-31
HRP20130167T1 (hr) 2013-03-31
IL213160A (en) 2013-12-31
CA2746423C (en) 2014-01-14
EA018118B1 (ru) 2013-05-30
PE20120077A1 (es) 2012-02-06
EP2379532B1 (en) 2013-02-20
UA101998C2 (ru) 2013-05-27
RS52739B (sr) 2013-08-30
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
ES2401558T3 (es) 2013-04-22
HK1160110A1 (en) 2012-08-10
EP2379532A1 (en) 2011-10-26
SI2379532T1 (sl) 2013-05-31
PT2379532E (pt) 2013-03-25
AU2009333433A1 (en) 2011-06-30
JP5705743B2 (ja) 2015-04-22
EA201170834A1 (ru) 2011-12-30
ECSP11011136A (es) 2011-07-29
JP2012512249A (ja) 2012-05-31
CY1113930T1 (el) 2016-07-27
MX2011006603A (es) 2011-09-27
CN102245597A (zh) 2011-11-16
AR074471A1 (es) 2011-01-19
BRPI0922468A2 (pt) 2020-08-04
ZA201103946B (en) 2012-10-31
KR20110084539A (ko) 2011-07-25
HN2011001446A (es) 2013-08-05
TW201029994A (en) 2010-08-16
CR20110339A (es) 2011-09-14
WO2010077758A1 (en) 2010-07-08
SG172222A1 (en) 2011-07-28
TWI436996B (zh) 2014-05-11
CN102245597B (zh) 2014-04-16
PA8850801A1 (es) 2010-07-27
IL213160A0 (en) 2011-07-31
AU2009333433B2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
CR20110339A (es) Compuestos útiles para inhibir chk1
PE20151654A1 (es) Inhibidores de cdc7
PA8841901A1 (es) Compuestos orgánicos
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
CL2017001209A1 (es) Inhibidor de cinasa aurora a
PA8852901A1 (es) Inhibidores de proteina cinasa
PA8740901A1 (es) Compuestos organicos
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
DOP2014000200A (es) Compuestos inhibidores de raf
UY32730A (es) Inhibidores de cyp17
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CR20110560A (es) Métodos de tratamiento para tumores sólidos
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
GT201200038A (es) Composicion para tratar la fibrosis quistica
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer

Legal Events

Date Code Title Description
FG Application granted